Understanding how Pseudomonas aeruginosa becomes resistant to cefiderocol
Evolved cefiderocol resistance and cross protection
['FUNDING_R01'] · CEDARS-SINAI MEDICAL CENTER · NIH-11050751
This study is looking at how a common bacteria that affects people with cystic fibrosis becomes resistant to a specific antibiotic, cefiderocol, so we can find better ways to treat lung infections in these patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CEDARS-SINAI MEDICAL CENTER (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-11050751 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which the bacteria Pseudomonas aeruginosa develops resistance to the antibiotic cefiderocol, particularly in patients with cystic fibrosis. The study focuses on identifying specific gene mutations that contribute to this resistance and exploring how these mutations can also protect other bacteria from being killed by cefiderocol. By using laboratory experiments, researchers aim to uncover the biological processes involved in antibiotic resistance, which could lead to improved treatment strategies for patients suffering from chronic lung infections. The findings may help in developing new approaches to combat antibiotic-resistant infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cystic fibrosis who are experiencing lung infections caused by Pseudomonas aeruginosa.
Not a fit: Patients who do not have cystic fibrosis or are not infected with Pseudomonas aeruginosa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with cystic fibrosis who are suffering from antibiotic-resistant lung infections.
How similar studies have performed: Previous research has shown success in understanding antibiotic resistance mechanisms, but this specific approach to cefiderocol resistance is novel.
Where this research is happening
LOS ANGELES, UNITED STATES
- CEDARS-SINAI MEDICAL CENTER — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JORTH, PETER ALLAN — CEDARS-SINAI MEDICAL CENTER
- Study coordinator: JORTH, PETER ALLAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: bacteria infection